COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership
Retrieved on:
Thursday, December 24, 2020
COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest, said Mei Mei Hu, co-founder and CEO of COVAXX.
Key Points:
- COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest, said Mei Mei Hu, co-founder and CEO of COVAXX.
- Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXXs vaccine candidate, UB-612.
- COVAXX will supply the bulk product and Aurobindo will manufacture the finished doses at its facilities in Hyderabad, India.
- Commenting on the development, Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said We are proud to join hands with COVAXX for developing the first-ever peptide-based vaccine to combat the COVID-19 pandemic.